Patents by Inventor Xiangping Qian

Xiangping Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Certain steroids and methods for using the same in the treatment of cancer
    Patent number: 10487108
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: November 26, 2019
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10471078
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 12, 2019
    Assignee: Suzhou NeuPharma Co., Ltd.
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10457641
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 29, 2019
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY
    Publication number: 20190307767
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: November 13, 2018
    Publication date: October 10, 2019
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS
    Publication number: 20190307677
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 13, 2019
    Publication date: October 10, 2019
    Inventors: Zhe YANG, Alex R. MUCI, Jeffrey WARRINGTON, Gustave BERGNES, Bradley P. MORGAN, Chihyuan CHUANG, Antonio ROMERO, Scott COLLIBEE, Xiangping QIAN, Pu-Ping LU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20190224218
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 31, 2018
    Publication date: July 25, 2019
    Inventor: Xiangping Qian
  • Certain chemical entities, compositions, and methods
    Patent number: 10344048
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: July 9, 2019
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Amino-pyrimidine skeletal muscle modulators
    Patent number: 10272030
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: April 30, 2019
    Assignee: Cytokinetics, Inc.
    Inventors: Zhe Yang, Alex R. Muci, Jeffrey Warrington, Gustave Bergnes, Bradley P. Morgan, Chihyuan Chuang, Antonio Romero, Scott Collibee, Xiangping Qian, Pu-Ping Lu
  • Certain chemical entities, compositions, and methods
    Patent number: 10179141
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 15, 2019
    Assignee: SUZHOU NEUPHARMA CO., LTD.
    Inventor: Xiangping Qian
  • Substituted quinazolines for inhibiting kinase activity
    Patent number: 10172868
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: January 8, 2019
    Assignee: NEUPHARMA, INC.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
    Patent number: 10137125
    Abstract: Benzenesulfonamide derivatives of quinoxaline that are kinase inhibitors, pharmaceutical compositions and methods of using these derivatives, e.g., for treatment of cancer are described.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 27, 2018
    Assignee: NEUPHARMA, INC.
    Inventors: Yong-Liang Zhu, Xiangping Qian
  • Substituted pyridazines as skeletal muscle modulators
    Patent number: 10076519
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: September 18, 2018
    Assignee: CYTOKINETICS, INC.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R. Muci, Xiangping Qian, Jeffrey Warrington, Zhe Yang, Pu-Ping Lu, Antonio Romero
  • Certain chemical entities, compositions, and methods
    Patent number: 10065932
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: September 4, 2018
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Certain chemical entities, compositions, and methods
    Patent number: 10065986
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: September 4, 2018
    Assignee: NeuPharma, Inc.
    Inventor: Xiangping Qian
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20180230128
    Abstract: Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: January 19, 2018
    Publication date: August 16, 2018
    Inventors: Yong-Liang ZHU, Xiangping QIAN
  • Substituted quinoxalines for inhibiting kinase activity
    Patent number: 10047059
    Abstract: Described herein are kinase inhibitors represented by Formula I: pharmaceutical compositions thereof, and uses thereof including but not limited to uses in treatment of cancer.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: August 14, 2018
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-liang Zhu
  • BEAUTYBERRY TOTAL GLYCOSIDES EXTRACT AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20180214500
    Abstract: Disclosed is a composition comprising an beautyberry total glycosides extract, and a method of preparation thereof, and the use of the composition thereof in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract thereof is prepared from the leaves of Callicarpa cathayana H.T. Chang or Callicarpa formosana Rolfe, and contains 18% to 45% verbascoside and 15% to 40% Arenarioside.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Inventors: Jingge Liu, Yijun Cheng, Jinguo Cao, Yongliang Zhu, Xiangping Qian
  • Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
    Patent number: 9994528
    Abstract: Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R2, R4, R5, R6, R7, R8, R9, X, Z1, Z2, Z3, Z4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: June 12, 2018
    Assignee: Cytokinetics, Inc.
    Inventors: Luke W. Ashcraft, Gustave Bergnes, Scott Collibee, Chihyuan Chuang, Jeff Gardina, Bradley P. Morgan, Alex R Muci, Xiangping Qian, Antonio Romero, Jeffrey Warrington, Zhe Yang
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20180134669
    Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.
    Type: Application
    Filed: October 16, 2017
    Publication date: May 17, 2018
    Inventors: Xiangping QIAN, Yong-Liang ZHU
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20180125866
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 10, 2017
    Publication date: May 10, 2018
    Inventor: Xiangping QIAN